New developments and future directions in the management of systemic lupus erythematosus - PubMed
4 hours ago
- #Autoimmune Disorders
- #Emerging Therapies
- #Clinical Trials
- Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder involving aberrant innate and adaptive immune interactions, with key pathogenetic axes including the type I interferon pathway and loss of B cell/plasma cell tolerance leading to autoantibody formation.
- SLE's clinical and pathogenetic heterogeneity has hampered clinical trials and novel therapy development, but since the 2011 FDA approval of belimumab, there has been an explosion in trials leading to approvals like anifrolumab for SLE and belimumab, voclosporin, and obinutuzumab for lupus nephritis.
- Multiple drugs with new targets have advanced through phase 1-3 clinical trials, promising improved outcomes, and this review focuses on recent and emerging treatments and their potential impact on future lupus management directions.
- Conflict of interest disclosures include author Kyriakos A Kirou receiving research grants, travel reimbursement, and consulting fees from various organizations, while other authors report no competing interests.